Drug Approval | July 10, 2024
Zydus receives final approval from USFDA for Sacubitril and Valsartan Tablets
Sacubitril and Valsartan combination is used to treat chronic heart failure in adults
Sacubitril and Valsartan combination is used to treat chronic heart failure in adults
Diroximel Fumarate Delayed-Release Capsules is indicated for the treatment of relapsing forms of multiple sclerosis
Olverembatinib, a novel drug developed by Ascentage Pharma with support from the National Major New Drug Development program
Doxycycline capsules are indicated for the treatment of only inflammatory lesions (papules and pustules) of rosacea in adult patients
Approval based on FLAURA2 results which showed Tagrisso plus chemotherapy extended median progression-free survival by nearly 9 months vs. standard of care
GL0034 administered once-weekly confirmed clinically meaningful weight loss and improved glucometabolic parameters over a 4-week treatment period in individuals with obesity
Approval based on CAPItello-291 results which showed this combination reduced the risk of disease progression or death by 50% vs. Faslodex alone in a biomarker-altered population
Second FDA approval for KRAZATI - reinforcing its potential across tumor types
Ascentage Pharma has executed an Exclusive Option to License Global Rights to Olverembatinib worldwide other than China and a few other areas
Dabigatran Etexilate Capsules are indicated for reduction of risk of stroke and systemic embolism in non-valvular atrial fibrillation in adult patients
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
